ReportsandReports - Diabetes Pipeline: Intense Activity to Meet Unmet Need

Original Source: Diabetes Pipeline Market

Buy Now: Market Research

Browse all CHI Healthtech Market Research Reports

Diabetes has serious consequences if it is not well treated. In 2010, the global prevalence of diabetes was estimated to have reached 285 million and it is predicted to reach 438 million in 2030. Available agents provide imperfect control of the disease, and the medical need for better therapies is widely recognized. This report discusses:

Pros and cons of marketed therapies and snapshots of the global diabetes market

Development pipelines and approaches that are being taken

Anticipated FDA filing dates for significant new products

Profiles of selected companies that are active in the field, including major and emerging players as well as specialist companies

Global market forecast to 2014, accounting for impacts of generics and new therapies

Expert interviews

Treatment of diabetes relies on a number of therapeutic interventions. A highly prevalent condition requiring treatment with multiple therapies generates a considerable demand for drugs. Diabetes Pipeline: Intense Activity to Meet Unmet Need begins by examining the current major products available for the treatment of diabetes and highlights the segmentation of this large market between oral and injectable treatments. In 2009, only six key players dominated the $29 billion diabetes market. We consider how near-term developments may impact the value of the global diabetes market and how new products may result in the emergence of significant new players.

This report then considers the large number of agents that are currently being developed for the treatment of diabetes, which seek to exploit a highly divergent range of potential targets. Although many of these seek to exploit new targets, a considerable number of new agents in development seek to exploit established approaches for the treatment of diabetes. The vast majority of new agents in development are directed toward the treatment of type II diabetes, with relatively few being developed principally for the treatment of type I diabetes. Almost all of the agents being developed for type I diabetes are novel insulin derivatives or formulations. Discussion of the extensive number of exploratory approaches to the development of new oral hypoglycemic agents is followed by discussion of the novel biological agents under investigation.

About Us

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:

Ms. Sunita

7557 Rambler road,

Suite 727, Dallas, TX 75231

Tel: +1-888-989-8004

http://reportsandreports.blogspot.com/

http://reportsandreports.proarticles.co.uk/

http://reportsnreports.wordpress.com/

ReportsandReports - Diabetes Pipeline: Intense Activity to Meet Unmet Need

By: ReportsandReports

POST COMMENT

Dealing with Diabetes during Pregnancy Managing Diabetes without Fear A Alimentação e a Diabetes tipo 2 Avandamet for Type 2 Diabetes Mellitus Diabetes Personalised Care Planning – background and overview Reversing Diabetes with the Diabetes Diet Plan Reverse diabetes with the Diabetes Diet Plan New Eating habits with the Diabetes diet Plan What is Gestational Diabetes - Causes, Symptoms and Treatment Why Diabetes Can Cause Bad Breath? Whyt You Should Start Exercising to Help Manage Your Diabetes Better Weight Loss And Diabetes: The Tale Of An Amazing Rebound Could White Flour Be Contributing to the Type 2 Diabetes Epidemic